Framycetin sulfate

Base Information

• Chemical Name: Framycetin sulfate
• CAS No.: 1405-10-3
• Deprecated CAS: 1391-66-8,53664-46-3
• Molecular Formula: C23H46N6O13^.3(H2SO4)
• Molecular Weight: 908.88
• Hs Code.: 29419000
• European Community (EC) Number: 223-969-3,248-770-9,215-773-1
• DSSTox Substance ID: DTXSID10948247
• Wikidata: Q27124126
• NCI Thesaurus Code: C66227,C75943
• RXCUI: 7300
• Metabolomics Workbench ID: 58680
• Mol file: 1405-10-3.mol

Synonyms:Antibiotic 10676;Framycetin;Framycetin Sulfate;Neomycin B;Neomycin B Sulfate;Soframycin;Sulfate, Framycetin;Sulfate, Neomycin B

Chemical Property of Framycetin sulfate

Chemical Property:

• Appearance/Colour: White powder
• Vapor Pressure: 0mmHg at 25°C
• Melting Point: >187°C (dec.)
• Refractive Index: 56 ° (C=10, H2O)
• Boiling Point: 1046.1oC at 760 mmHg
• Flash Point: 586.5oC
• PSA: 436.09000
• LogP: -4.26550
• Storage Temp.: 2-8°C
• Solubility.: H2O: 50 mg/mL As a stock solution. Stock solutions should b
• Water Solubility.: Soluble in water
• Hydrogen Bond Donor Count: 15
• Hydrogen Bond Acceptor Count: 23
• Rotatable Bond Count: 9
• Exact Mass: 712.27966526
• Heavy Atom Count: 47
• Complexity: 953

Purity/Quality:

99% ,99.9%, ^*data from raw suppliers

Neomycin Sulfate ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn,Xi
• Statements: 42/43-22
• Safety Statements: 23-36/37-45-22-36-24/25

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N.OS(=O)(=O)O
• Isomeric SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N.OS(=O)(=O)O
• Recent ClinicalTrials: SURGIcal COmplication and MIcrobiome ChangeS in Colorectal Surgery
• Recent EU Clinical Trials: Phase IV, unicentric, randomized and open study to confirm the decrease of the incidence of the surgical site infection after elective right hemicolectomy with anterographic mechanical preparation associated with oral and intravenous antibiotic therapy versus oral and intravenous antibiotic and versus only intravenous antibiotic
• Uses: NEOMYCIN SULFATE is an aminoglycoside antibiotic found in many topical medications. NEOMYCIN SULFATE has been used as a preventive measure for hepatic encephalopathy and hypercholesterolemia. NEOMYCIN SULFATE is an aminoglycoside antibiotic produced by S. fradiae that inhibits protein translation by binding to the small subunit of prokaryotic ribosomes. It blocks voltage-sensitive Ca2+ channels and is a potent inhibitor of skeletal muscle sarcoplasmic reticulum Ca2+ release. NEOMYCIN SULFATE has been shown to inhibit inositol phospholipid turnover, phospholipase C, and phosphatidylcholine-phospholipase D activity (IC50 = 65 μM). It is highly effective against Gram-positive and Gram-negative bacteria and is commonly used for the prevention of bacterial contamination of cell cultures. Neomycin sulfate is an antibiotic (can be used effectively against most bacteria that cause skin, eye and outer ear infections); broad-spectrum antibiotic in topical creams, powders, ointments, eye and ear drops; systemic antibiotic and growth promotor in veterinary use.
• Indications: This drug is obtained from species of the actinomycete Streptomyces and is an aminoglycoside antibiotic (as are streptomycin, gentamicin, and kanamycin) effective against most aerobic gram-negative organisms. Group A streptococci are relatively resistant. Neomycin acts to inhibit bacterial protein synthesis by irreversibly binding to the 30S subunit. It is responsible for a greater incidence of allergic contact sensitivity than any other topical antibiotic. This diagnosis often remains hidden, because morphologically the eruption is of a mild eczematous nature. Rarely, anaphylaxis may occur.
• Clinical Use: In a search for antibiotics less toxic than streptomycin,Waksman and Lechevalier isolated neomycin (Mycifradin,Neobiotic) in 1949 from Streptomyces fradiae. Since then, theimportance of neomycin has increased steadily, and today, itis considered one of the most useful antibiotics for the treatmentof GI infections, dermatological infections, and acutebacterial peritonitis. Also, it is used in abdominal surgery toreduce or avoid complications caused by infections from bacterialflora of the bowel. It has broad-spectrum activityagainst various organisms and shows a low incidence of toxicand hypersensitivity reactions. It is absorbed very slightlyfrom the digestive tract, so its oral use ordinarily does not produce any systemic effect. The development of neomycinresistantstrains of pathogens is rarely reported in those organismsagainst which neomycin is effective.Neomycin as the sulfate salt is a white to slightly yellow,crystalline powder that is very soluble in water. It is hygroscopicand photosensitive (but stable over a wide pH rangeand to autoclaving). Neomycin sulfate contains the equivalentof 60% of the free base.Neomycin, as produced by S. fradiae, is a mixture ofclosely related substances. Included in the “neomycin complex”is neamine (originally designated neomycin A) andneomycins B and C. S. fradiae also elaborates another antibiotic,the fradicin, which has some antifungal propertiesbut no antibacterial activity. This substance is not present in“pure” neomycin.
• Drug interactions: Potentially hazardous interactions with other drugs Antibacterials: absorption of phenoxymethylpenicillin reduced; increased risk of nephrotoxicity with colistimethate or polymyxins and possibly cephalosporins; increased risk of ototoxicity and nephrotoxicity with capreomycin or vancomycin. Anticoagulants: altered INR with coumarins or phenindione. Ciclosporin: increased risk of nephrotoxicity. Cytotoxics: possibly reduced methotrexate absorption; bioavailability of sorafenib reduced; increased risk of nephrotoxicity and possibly of ototoxicity with platinum compounds. Diuretics: increased risk of ototoxicity with loop diuretics. Muscle relaxants: enhanced effects of suxamethonium and non-depolarising muscle relaxants. Parasympathomimetics: antagonism of effect of neostigmine and pyridostigmine. Tacrolimus: increased risk of nephrotoxicity